Contextual Main Account News

Contextual Genomics Receives DAP Accreditation for Testing and Informatics System

Vancouver, Canada – May 10, 2017 – Contextual Genomics Inc. (“Contextual”), developers of genomic cancer tests and computational systems, is pleased to announce it has received full accreditation from the Diagnostic Accreditation Program (DAP). Contextual is the first laboratory to receive full accreditation in Molecular Diagnostics from DAP. DAP, a program of the College of Physicians and Surgeons of British …

Contextual Main Account News

Contextual Genomics Named to 2017 Life Science Ready to Rocket List

Vancouver, Canada – April 10, 2017 – Contextual Genomics Inc. (“Contextual”), developers of cancer tests and computational systems, is pleased to announce it has been named to the 2017 Life Science Ready to Rocket List. Contextual Genomics was recognized for expanding its distribution of genomic cancer testing to international partner laboratories. Ready to Rocket (www.readytorocket.com) identifies the top private B.C. companies …

Contextual Main Account News

Sonic Healthcare and Contextual Genomics Broaden Access to Leading Edge Cancer Genomic Testing

Vancouver, Canada and Macquarie Park, Australia – January 03, 2017 – Contextual Genomics Inc. (“Contextual”), developers of molecular-based cancer tests, and Sonic Healthcare Limited (“Sonic”) (SHL.AX), a global leader in medical diagnostic services, announced they have signed an agreement enabling Sonic to provide quality-assured Next Generation Sequencing (NGS)-based genetic testing to cancer patients in Australia and other parts of the …

Contextual Main Account News

Genome BC supporting revolutionary cancer screening program

The National Access Program for Cancer Testing (NAP) is a groundbreaking move to establish equitable access to state-of-the-art cancer diagnostics across Canada. Led by Contextual Genomics, the program is supported by a consortium of companies and academic institutions. In NAP, Contextual Genomics’s Find-ItTM (Cancer Hotspot Panel) profiles a patient’s tumour to match that patient to the most effective treatment options, …

Contextual Main Account News

Contextual Genomics and the Personalized Medicine Initiative Launch Phase 2 Testing of its National Access Program Cancer Genomics Test

1500 patients will be given access to the Find It™ hotspot cancer genomics test, which focuses on 90 known tumour mutations.   Vancouver, BC – March 14, 2016 – Contextual Genomics, developers of genomics-based cancer tests, and the Personalized Medicine Initiative (PMI), an organization bringing molecular-based medicine to Canadians, are pleased to announce they have launched the National Access Program’s Phase …

Contextual Main Account News

Contextual Genomics Laboratory Receives Accreditation from College of American Pathologists (CAP), the Highest Laboratory Standard Worldwide

Vancouver, BC – October 21, 2015 – Contextual Genomics, developers of genomics-based cancer tests, has been awarded accreditation by the Accreditation Committee of the College of American Pathologists (CAP). The CAP Laboratory Accreditation, the highest laboratory standards accreditation internationally, is recognized by the U.S. federal government as equal-to or more-stringent-than the government’s own laboratory inspection programs. “It is Contextual’s goal …

Contextual Main Account News

Contextual Genomics and the NCIC Clinical Trials Group Announce Scientific Collaboration to Study Cancer Gene Mutations

Vancouver, BC – September 15, 2015 – Contextual Genomics, developers of genomics-based cancer tests, is pleased to announce a scientific collaboration with the NCIC Clinical Trials Group (NCIC CTG) to research gene mutations in cancer. As part of the collaboration, NCIC CTG will use Contextual’s genomics-based cancer tests to determine the cancer mutations present in patients in a Phase 2 clinical trial conducted …

Contextual Main Account News

Contextual Genomics and the Personalized Medicine Initiative Add ArcherDX, the Sixth Consortium Partner, to its National Access Project

Vancouver, BC – August 3, 2015 – Contextual Genomics, developers of genomics-based cancer tests, and the Personalized Medicine Initiative (PMI), an organization bringing molecular-based medicine to Canadians, are pleased to welcome its sixth consortium partner, ArcherDX, to the National Access Project. ArcherDX develops best-in-class next generation sequencing (NGS) applications. The goal of the National Access Project is to make genomics …

Contextual Main Account News

HIT Consultant: Contextual Genomics is Canada’s Top 20 Digital Health Company to Watch

3. Contextual Genomics Of all the health issues in developing countries, cancer is one condition that affects populations on a wide-scale basis without discrimination. Having crafted diagnostic tests based on gene mutations, this company aims to identify therapeutic targets for patients, acquired drug resistant mutations and mutations that may have prognostic or diagnostic implications for patient care. Founded: 2012 Founders: David …

Contextual Main Account News

Contextual Genomics and the Personalized Medicine Initiative Sign Sequencing Technology Leader Illumina to National Access Project

Vancouver, BC – July 17, 2015 – Contextual Genomics, developers of genomics-based cancer tests, and the Personalized Medicine Initiative (PMI), an organization bringing molecular-based medicine to Canadians, are pleased to announce global sequencing technology leader, Illumina, Inc. has joined its National Access Project consortium. The National Access Project aims to make genomics testing a standard practice in cancer care to …

Contextual Main Account News

National Access Project for Cancer Testing Gains Momentum. Sanofi is the newest partner in Consortium offering Canadian patients testing for cancer tumor mutations.

Vancouver, BC – April 21, 2015 – Contextual Genomics, a molecular diagnostics company developing genomic based cancer tests, and the Personalized Medicine Initiative (PMI), an organization bringing molecular-based medicine to Canadians, are pleased to announce that Sanofi (EURONEXT: SAN and NYSE: SNY) is the latest partner to join their National Access Project for Cancer Testing consortium. As part of its …

Contextual Main Account News

Le Projet national d’accessibilité aux analyses oncologiques prend de l’élan. Sanofi est le tout nouveau partenaire du Consortium offrant aux patients canadiens des analyses pour les mutations des tumeurs cancéreuses.

Vancouver, C.-B. – avril 21, 2015 – Contextual Genomics, une entreprise spécialisée en diagnostic moléculaire qui conçoit des tests génomiques pour le cancer, et Personalized Medicine Initiative (PMI), une organisation qui favorise l’accessibilité de la médecine moléculaire aux Canadiens, sont ravies d’annoncer que Sanofi (EURONEXT: SAN et NYSE : SNY) est le plus récent partenaire à se joindre au consortium du …

educedesign News

Contextual Genomics and the Personalized Medicine Initiative Welcome Pfizer Canada to Consortium for National Access Project for Cancer Testing

Vancouver, BC – March 4, 2015 – Contextual Genomics, a molecular diagnostics company developing genomic based cancer tests, and the Personalized Medicine Initiative (PMI), an organization bringing molecular-based medicine to Canadians, are pleased to welcome Pfizer Canada to its National Access Project consortium. The National Access Project’s aim is to make genomic cancer testing available to any Canadian diagnosed with …

educedesign News

Contextual Genomics et Personalized Medicine Initiative accueillent Pfizer Canada au sein du consortium du Projet national d’accessibilité aux analyses oncologiques

Vancouver, C.-B. – 4 mars 2015 – Contextual Genomics, une entreprise de diagnostic moléculaire qui conçoit des tests génomiques destinés aux analyses oncologiques, et Personalized Medicine Initiative (PMI), un organisme spécialisé en médecine moléculaire, sont heureux d’accueillir Pfizer Canada au sein du consortium du Projet national d’accessibilité. Le Projet vise à rendre les tests génomiques accessibles à tous les Canadiens …